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ORIGINAL ARTICLE
Introduction: Most clinically available small-molecule kinase 
inhibitors are multi-targeted and can inhibit multiple kinases. 
Our driving hypothesis was that one of these multi-targeted 
tyrosine kinase inhibitors (TKIs) would have antiproliferative 
activity against ROS1 translocated non–small-cell lung cancer 
(NSCLC).
Methods: We selected NSCLC cell lines—A549 (KRAS G12S), 
NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), 
and HCC78 (SLC34A2-ROS1)—to evaluate the antiproliferative 
effects of submicromolar concentrations of the multitargeted TKIs 
imatinib, sorafenib, erlotinib, and crizotinib.
Results: Imatinib and sorafenib were unable to significantly 
inhibit proliferation of the aforementioned cell lines. Erlotinib 
only inhibited EGFR mutated NCI-H3255, as expected. 
Crizotinib displayed dose-dependent inhibition of anaplastic 
lymphoma kinase translocated NCI-H3122 and also ROS1-
translocated HCC78. The SLC34A2-ROS1 translocated HCC78 
cell line had phosphorylated levels of ROS1, AKT, and ERK 
inhibited by submicromolar doses of crizotinib, and subse-
quently underwent apoptosis.
Conclusions: The ROS1-translocated HCC78 cell line was sensitive 
to inhibition by the multitargeted ALK/MET/RON/ROS1 inhibitor 
crizotinib. Preclinical data supports the clinical development of cri-
zotinib for ROS1-translocated NSCLC.
Key Words: Lung cancer, Non–small-cell lung cancer, Tyrosine 
kinase, Kinase inhibitor, Epidermal growth factor receptor, 
Anaplastic lymphoma kinase, ALK, ROS1, Crizotinib.
(J Thorac Oncol. 2012;7: 1086–1090)
The human kinome consists of more than 500 structur-ally related enzymes that either phosphorylate the amino 
acids tyrosine, or serine and threonine, or both. Kinase 
inhibitors have revolutionized the palliative care of patients 
with advanced cancer. These drugs usually compete with 
adenosine triphosphate within the active binding pocket of 
these enzymes. Most,  if not all, of the currently clinically 
available and approved small-molecule kinase inhibitors are 
multitargeted and can inhibit multiple kinases.1 One can cite 
imatinib, sorafenib, erlotinib, and crizotinib as examples. 
Imatinib was approved for use in Philadelphia chromosome-
positive chronic myeloid leukemia and stem cell factor/
proto-oncogene c-Kit (KIT)-positive metastatic gastroin-
testinal stromal tumor, and has inhibitory activity against 
v-abl abelson murine leukemia viral oncogene homologue 
1, platelet-derived growth factor receptor, KIT, among other 
kinases.1 Sorafenib was approved for use in advanced renal 
cell and hepatocellular carcinomas, and has activity against 
v-raf-1 murine leukemia viral oncogene homologue 1, v-raf 
murine sarcoma viral oncogene homologue B1 (BRAF), 
KIT, Fms-like tyrosine kinase 3, Ret proto-oncogene, vascu-
lar endothelial growth factor receptor (VEGFR)-1, VEGFR-
2, VEGFR-3, and platelet-derived growth factor receptor 
among other kinases.2 Erlotinib was approved for meta-
static non–small-cell lung cancer (NSCLC) and pancreatic 
cancer, and has activity against epidermal growth factor 
receptor (EGFR), mitogen-activated protein kinase 1, inte-
grin-linked kinase, tyrosine-protein kinase abelson-related 
gene, among other tyrosine and serine/threonine kinases.3 
Crizotinib was approved for use in metastatic NSCLC that 
is anaplastic lymphoma kinase (ALK)-positive, and can 
inhibit ALK, hepatocyte growth factor receptor (MET), 
recepteur d’origine nantais (RON), among other kinases.4,5
NSCLCs are the leading cause of cancer mortality 
worldwide and even small subgroups constitute important 
cohorts for which effective therapies are needed. Over the 
past decade, the molecular heterogeneity of NSCLCs has 
begun to be unraveled, and it is now clear that some tumors 
are characterized by “driver” oncogene mutations in kinases.6 
The most prevalent mutated oncogenes identified in NSCLCs 
are v-ki-ras2 Kirsten rat sarcoma viral oncogene homologue 
(KRAS), EGFR, ALK (where translocations and not mutations 
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are present), proto-oncogene tyrosine kinase c-ROS 1 (ROS1) 
(again, where translocations and not mutations are seen), 
ERBB2, BRAF, and PIK3CA.7
We sought to screen NSCLC cell lines driven by 
mutated/translocated KRAS, EGFR, ALK, and ROS1 
against multitargeted tyrosine kinase inhibitors (TKIs) that 
are already approved. Our driving hypothesis was that one 
of these clinically available multitargeted TKIs, because of 
their known promiscuity,1 could have antiproliferative activity 
against ROS1-driven tumors. ROS1 is a tyrosine kinase with 
similarities—much like ALK—to the insulin growth factor 
receptor family.8,9 It has unknown ligands and function, but 
has been found to be translocated in a diverse array of tumor 
types including glioblastomas, cholangiocarcinomas, and 
NSCLCs.9–11 It is hoped that identification of a commercially 
available multitargeted TKI with preclinical activity against 
ROS1-driven cancers would lead to a rapid translation into 
confirmatory clinical studies.
MATERIALS AND METHODS
Reagents
Erlotinib, sorafenib, imatinib, and crizotinib were pur-
chased from LC Laboratories (Woburn, MA). All reagents 
were dissolved in dimethyl sulfoxide and stored at −808C.
Cell Culture
A549, NCI-H3122 (H3122), NCI-H3255 (H3255), and 
HCC78 cells were maintained in Roswell Park Memorial 
Institute 1640 medium (Mediatech, Manassas, VA) supple-
mented with 10% fetal bovine serum. All cells were grown at 
37°C in a humidified atmosphere with 5% CO
2
.
Cell Line Proliferation Assays
Cells were plated in 96-well plates, allowed to attach, 
and then treated with or without TKIs for 72 hours. Cell via-
bility was determined by CellTiter 96 Aqueous One solution 
proliferation kit (Promega, Madison, WI) according to the 
manufacturer’s protocol.
Western Blotting and Antibodies
Cells were lysed in cell lysis buffer containing 20 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM ethylenediaminetet-
raacetic acid, 1 mM ethylene glycol tetraacetic acid, 1% Triton, 
1 mM beta-glycerophosphate, 1 mM Na
3
VO
4
, and 1 mM NaF. 
Protease inhibitor cocktail set III (Calbiochem, La Jolla, CA) 
and 1 mM phenylmethanesulfonylfluoride or phenylmethyl-
sulfonyl fluoride was added to inhibit the degradation of pro-
tein. Lysates were cleared by centrifugation (14,000 rpm for 
5 minutes) and boiled with sodium dodecyl sulfate sample 
buffer for 3 minutes. Forty μg lysates were separated by 8% 
sodium dodecyl sulfate-polyacrylamide gel, transferred to 
polyvinylidene fluoride membrane, and analyzed with the use 
of Pierce-enhanced chemiluminescence Western blotting sub-
strate (Thermo Scientific, Waltham, MA). Total EGFR anti-
body was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). Total extracellular signal regulating kinase 1/2 
(ERK 1/2) antibody was purchased from BD Transduction 
Laboratories (Lexington, KY). Phospho-EGFR (pT1068) 
antibody was purchased from Invitrogen (Carlsbad, CA). 
Protein kinase B (AKT), phospho-AKT (pS473), phospho-
ERK 1/2 (pT202/pY204), phospho-ALK, ALK, phospho-
ROS (pT2274), and ROS were purchased from Cell Signaling 
Technology (Beverly, MA). Poly adenosine diphosphate-
ribose polymerase (PARP) and cleaved PARP were purchased 
from Cell Signaling Technology (Beverly, MA). All primary 
antibodies were diluted 1:1000, whereas their recommended 
secondary antibodies were diluted 1:10,000.
Statistical Analysis
The paired Student’s t test was used to determine the 
difference in cell viability between dimethyl sulfoxide and 
inhibitor-treated cells.
RESULTS
Proliferation of Oncogene-Driven NSCLC Cell 
Lines Upon Exposure to Multitargeted Kinase 
Inhibitors
We selected four representative cell lines with known 
oncogenic mutations: A549 (KRAS G12S), H3255 (EGFR 
L858R), H3122 (EML4-ALK E13;A20), and HCC78 
(SLC34A2-ROS1).
Imatinib was not able to significantly alter viability of 
any of the cell lines tested (Fig. 1A). Sorafenib minimally 
decreased the proliferation rate of all cell lines, but in none of 
the cells did the cell viability fall below 70% of control condi-
tions (Fig. 1B). Erlotinib was only able to inhibit the prolifera-
tion of the EGFR-mutated H3255 cell line in submicromolar 
concentrations (Fig. 1C), achieving 63.6% inhibition at 1 μM 
(p = 0.0012) and 89.4% inhibition at 1μM (p = 0.0031).
Crizotinib had dose-dependent inhibitory activity 
against H3122 and HCC78 in submicromolar concentra-
tions (Fig. 1D). At 0.1 μM, crizotinib achieved 48.6% inhibi-
tion of H3122 (p = 0.0087) and 31.1% inhibition of HCC78 
(p = 0.0349). At 1 μM, crizotinib achieved 80.3% inhibi-
tion of H3122 (p = 0.0013) and 58.1% inhibition of HCC78 
(p = 0.0072). These results indicated that crizotinib had antip-
roliferative activity in ALK and ROS1-translocated cells.
Crizotinib and Inhibition of ROS1 and 
Downstream Targets in HCC78
We next evaluated the ability of crizotinib to inhibit 
ROS1, the phosphatidylinositol-3-kinases (PI3K)/AKT, 
and the ERK/mitogen-activated protein kinase (MAPK) 
pathways.
HCC78 cells had levels of phosphorylated ROS1, corre-
sponding to the expected size of fusion oncogene SLC34A2-
ROS1, inhibited by concentrations of 0.1 and 1 μM of 
crizotinib (Fig. 2). Both phosphorylated AKT and ERK 1/2 
were similarly inhibited by 0.1 and 1 μM of crizotinib in 
HCC78 cells but not in the EGFR mutant H3255 cell or KRAS 
mutated A549 cell (Fig. 2). H3122 cells, with an ALK trans 
had levels of phosphorylated ALK inhibited by concentra-
tions of 0.1 and 1 mM of crizotinib (Fig. 2). Phosphorylated 
AKT was inhibited by crizotinib in H3122 cells as in HCC78, 
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FIGURE 1.  Proliferation assay 
evaluating multitargeted tyrosine 
kinase inhibitors  in NSCLC 
cell lines. Cells were plated at 
a density of 1500 cells/well for 
A549, 2500 cells/well for H3122, 
5000 cells/well for H3255, and 
2000 cells/well for HCC78. All 
experiments were performed in 
triplicate. A, Inhibitory profile 
of imatinib (0, 0.01, 0.1, and 
1 μM). B, Inhibitory profile of 
sorafenib (0, 0.01, 0.1, and 1 
μM). C, Inhibitory profile of erlo-
tinib (0, 0.01, 0.1, and 1 μM). D, 
Inhibitory profile of crizotinib  
(0, 0.01, 0.1, and 1 μM). Results 
are displayed in bar columns 
with standard deviation (SD) 
in relation to cell viability. 
Treatment with dimethyl sulfox-
ide (indicated as a concentration 
of 0) was used as the standard 
for 100% cell viability in each 
cell line.  
* indicates a p < 0.05 (see text 
for exact p values) for erlotinib 
and crizotinib-treated cells.
FIGURE 2.   Western blot analy-
sis of protein extracts from cells 
treated with crizotinib. A549, 
H3122, HCC78, and H3255 
cells were treated with dimethyl 
sulfoxide (indicated as concen-
tration of 0), 0.1 or 1 μM of cri-
zotinib for 24 hours. The figure 
shows the levels of phosphory-
lated ALK, total ALK (expected 
size of EML4-ALK E13;A20 
of approximately 120kDa), 
phosphorylated ROS, total ROS 
(expected size of SLC34A2-ROS 
of approximately 70 kDa with 
three identified isoforms of 85, 
70, and 59 kDa; wild-type ROS 
has a size of 258 kDa), phospho-
rylated AKT, total AKT (size of 60 
kDa), phosphorylated ERK 1/2 , 
total ERK 1/2 (sizes of 42 and 44 
kDa), and actin (size of 45 kDa). 
Wild-type ROS was not detected 
in either HCC78 or H3255 (data 
not shown).
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whereas levels of ERK1/2 were less inhibited (Fig. 2). Hence, 
crizotinib was able to inhibit ALK and ROS1, and its putative 
downstream targets.
Crizotinib and Apoptosis in HCC78
We also evaluated the ability of crizotinib to induce apop-
tosis in the ROS1-translocated cell line HCC78. Exposure to 1 
μM of crizotinib, for 48 hours, induced cleavage of PARP—a 
marker of caspase cleavage of PARP and hence apoptosis—in 
H3122 and HCC78 but not in H3255 or A549 cells (Fig. 3). 
These results indicate that crizotinib not only inhibits prolif-
eration (Fig. 1) but also induces apoptosis (Fig. 3) in NSCLC 
cells driven by ALK or ROS1 fusion genes.
DISCUSSION
We screened four multitargeted kinase inhibitors (ima-
tinib, sorafenib, erlotinib, and crizotinib) against cells driven 
by oncogenic KRAS (A549), EGFR (H3255), ALK (H3122), 
and ROS1 (HCC78). Our results confirmed that EGFR-
mutated and ALK-translocated NSCLCs were only sensitive 
to TKIs that inhibited EGFR (erlotinib) and ALK (crizotinib), 
respectively. Of most interest, we were able to demonstrate 
that the ROS1-translocated HCC78 NSCLC cell line was sen-
sitive to crizotinib, and that crizotinib inhibited ROS1 and its 
downstream targets with the induction of apoptosis in this 
cell line.
The ROS1 tyrosine kinase is an orphan kinase with 
unknown ligands and unclear normal function.8 It is spatially 
and temporally regulated during normal development, and 
has been described as the kinase partner of translocations in 
some cancer types.9 In glioblastomas12 and cholangiocarcino-
mas,10 translocations involving fused in glioblastoma (FIG) 
and ROS1 (FIG-ROS1) have been identified. In NSCLCs, 
two translocations were described in 2007: CD74-ROS1 and 
SLC34A2-ROS1.11 The frequency of ROS1 translocations in 
NSCLC seems to be less than  2%.13,14 One report disclosed 
that 1% of lung adenocarcinomas from never smokers har-
bored ROS1 translocations.13 Another report determined that 
1.7% of the 1073 tumors screened were ROS translocated, 
with this gene abnormality enriched in never smokers.14 In 
Japanese patients with NSCLC, the frequency of ROS1 trans-
locations was recently reported to be 0.9% (13 of 1476) for all 
NSCLCs and 1.2% (13 of 1116) for lung adenocarcinomas.15
The concept of targeting ROS1 in ROS1-translocated 
NSCLCs with multi-targeted kinase inhibitors was enter-
tained by us after evaluating the observations made by other 
groups, which demonstrated that (1) an NSCLC cell line with 
SLC34A2-ROS1 (HCC78) was dependent on ROS signaling 
for survival11; (2) ROS1, like ALK, had similarities with the 
insulin growth factor receptor family8; (3) an in vitro system 
driven by FIG-ROS1 was inhibited by the potent ALK TKI 
TAE68410; (4) the ALK TKI AP26113 was active against 
ROS1 using an in vitro kinase assay16; and (5) novel ROS1 
TKIs being developed had inhibitory activity against ABL, 
BRAF, RON, and MET among other kinases.12
The aforementioned reports support our observation that 
the ROS1-translocated HCC78 NSCLC cell line was sensi-
tive to inhibition by the multitargeted ALK/MET/RON/ROS1 
inhibitor crizotinib. Indeed, others have recently shown that 
HCC78 cells were inhibited by crizotinib and that one patient 
with ROS1-translocated NSCLC achieved a partial response 
to 250 mg twice daily of crizotinib.14 The data presented in 
this study not only reproduced the results of those authors (the 
inhibition of HCC78 by crizotinib was similar in both reports) 
but also added important information to their observations. 
In their report, they did not evaluate other multitargeted TKIs 
against HCC78 or the ability of crizotinib to inhibit PI3K/
AKT and ERK/MAPK in these cells. We demonstrated that 
inhibition of ROS1 was only achieved with crizotinib and was 
linked to inhibition of AKT and ERK. We were also able to 
show that crizotinib induces apoptosis in HCC78 cells.
Crizotinib has been extensively studied in humans.12 It 
is bioavailable, has a favorable pharmacokinetic profile, is 
generally safe (major side effects include nausea, vomiting, 
diarrhea, visual field disturbances, edema, liver function test 
abnormalities among others) and was approved by the Food 
and Drug Administration in 2011 for use in metastatic 
NSCLC that is positive for ALK translocations.3,4,12 It also has 
clinical activity against ALK-translocated anaplastic large-
cell lymphoma and MET-amplified glioblastoma, NSCLC, 
FIGURE 3.  Western blot 
analysis of protein extracts from 
cells treated with crizotinib. 
A549, H3122, HCC78, and 
H3255 cells were treated with 
1 μM of crizotinib for 48 hours 
(h). The figure shows levels of 
full-length PARP, detected by 
using a PARP antibody, and 
cleaved PARP, detected by using 
a cleaved PARP antibody, in 
these cells. PARP cleavage was 
only observed in H3122 and 
HCC78 cell extracts. PARP, Poly 
(adenosine diphosphate -ribose) 
polymerase.
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and esophagogastric tumors.12 Therefore, crizotinib is an 
attractive multitargeted TKI that could see its use expanded to 
a diverse array of tumor types that are dependent on kinases 
that it can inhibit.
In summary, our data provide a preclinical rationale 
for further clinical testing of crizotinib for advanced ROS1-
translocated NSCLCs.
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